Deborah L Keller
CIK 1352992 · CEO, Covance Drug Development · last filed 2026-05-06
Deborah L Keller is a CEO, Covance Drug Development who has filed 41 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for WSTw, was dated May 6, 2026. Across all open-market trades the lifetime net is −$5.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.36M
3
41
-$5.91M
Holdings By Company
Recent Filings
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-06 | WSTw | Grant (A) | +791 | $0 | EDGAR |
| 2025-05-08 | WSTw | Grant (A) | +1,071 | $0 | EDGAR |
| 2024-04-25 | WSTw | Grant (A) | +564 | $0 | EDGAR |
| 2023-04-27 | WSTw | Grant (A) | +616 | $0 | EDGAR |
| 2022-05-26 | WSTw | Grant (A) | +632 | $0 | EDGAR |
| 2021-05-06 | WSTw | Grant (A) | +577 | $0 | EDGAR |
| 2020-05-07 | WSTw | Grant (A) | +975 | $0 | EDGAR |
| 2019-05-09 | WSTw | Grant (A) | +1,565 | $0 | EDGAR |
| 2019-01-03 | WSTw | Grant (A) | — | $0 | EDGAR |
| 2018-10-02 | WSTw | Grant (A) | — | $0 | EDGAR |